Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer (Q35581391)

9 August 2017

1 reference

title

Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer (English)

1 reference

9 August 2017

angiogenesis inhibitor

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00308-8

31 March 2024

author name string

Srikala S. Sridhar

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14611919

31 March 2024

Frances A. Shepherd

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14611919

31 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14611919

31 March 2024

publication date

1 December 2003

1 reference

full work available at URL

9 August 2017

https://api.elsevier.com/content/article/PII:S0169500203003088?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00308-8

https://api.elsevier.com/content/article/PII:S0169500203003088?httpAccept=text/plain

31 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00308-8

31 March 2024

1 reference

9 August 2017

42 Suppl 1

1 reference

9 August 2017

S81-91

1 reference

9 August 2017

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Current approaches to targeting cancer using antiangiogenesis therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Endothelial proliferation in tumours and normal tissues: Continuous labelling studies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Angiogenesis and non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Tumor angiogenesis: past, present and the near future

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Angiogenesis: regulators and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Development of matrix metalloproteinase inhibitors in cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Changing views of the role of matrix metalloproteinases in metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Expression and Prognostic Significance of Metalloproteinases and Their Tissue Inhibitors in Patients With Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Screening of novel matrix metalloproteinases (MMPs) in human fetal membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Matrix metalloproteinase inhibition: a review of anti-tumour activity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Marimastat (BB2516): current status of development

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Angiogenesis inhibitors in clinical development for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Tiny dancers: the integrin-growth factor nexus in angiogenic signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Post-transcriptional regulation of vascular endothelial growth factor by hypoxia.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

The influence of tumour resection on angiostatin levels and tumour growth--an experimental study in tumour-bearing mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Phase I study of recombinant human endostatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Natural interferon alfa as maintenance therapy for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900308-8

7 January 2021

Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion

15

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00308-8

Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis

31 March 2024

36

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00308-8

Vascular endothelial growth factor: molecular and biological aspects

31 March 2024

44

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00308-8

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types

31 March 2024

45

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00308-8

Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma

31 March 2024

83

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00308-8

31 March 2024

Identifiers

1 reference

9 August 2017

1 reference